Over the last 12 months, one AEON Biopharma, Inc. the people running the company added shares in open-market trades, about $242,000 in total, and none of them sold.
LYNCH TIMOTHY P (10% Owner) made the biggest buy, worth around $242,000.
On the institutional side, 22 funds reported holding AEON at the end of Q2 2026, and more funds bought than sold. Looking at the quarterly pattern: Last full quarter: net buying by insiders. Insiders bought in 2 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | LYNCH TIMOTHY P | 10% Owner | Buy | 1,150,000 | $0.21 | $242K | SEC |
| May 23, 2025 | FISCHER JOST | Director | Buy | 60,000 | $0.49 | $29K | SEC |
| May 21, 2025 | FISCHER JOST | Director | Buy | 60,000 | $0.51 | $31K | SEC |
| May 21, 2025 | FISCHER JOST | Director | Buy | 50,000 | $0.50 | $25K | SEC |
| Aug 14, 2023 | Strathspey Crown Holdings Group, LLC | 10% Owner | Sell | 7,380,394 | $10.00 | $73.8M | SEC |
In the last 12 months AEON Biopharma, Inc. insiders made open-market purchases worth about $242,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in AEON was filed on 2026-08-21.
22 investment managers reported holding AEON in SEC Form 13F filings for Q2 2026.
No congressional trades in AEON were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).